Vidarabine


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : Ophth Keratoconjunctivitis; Herpes simplex keratitis As 3% oint: Apply 5 times/day at 3-hr intervals until corneal re-epithelisation, then twice daily for another 7 days to prevent recurrence.
Dosage Details
Ophthalmic
Herpes simplex keratitis, Keratoconjunctivitis
Adult: Apply 3% eye ointment 5 times daily every 3 hr until corneal re-epithelialisation, then bid for another 7 days to prevent recurrence. Re-evaluate if there is no sign of improvement after 7 days of treatment or complete re-epithelisation has not occurred by 21 days.
Contraindications
Hypersensitivity. Concomitant admin with a corticosteroid.
Special Precautions
Consider alternative therapy if no improvement after 7 days or complete re-epithelisation has not occurred within 21 days. Use under close supervision of ophthalmologist. Pregnancy; lactation.
Adverse Reactions
Irritation; pain; superficial punctate keratitis; photophobia; lachrymation; blockage of lachrymal duct; temporary visual haze.
Action
Description: Vidarabine, a purine neucleoside, interferes in the early stages of viral DNA synthesis. It is phosphorylated intracellularly to the triphosphate and may also be incorporated into the viral DNA. It is active against Herpes simplex virus types 1 and 2, varicella-zoster virus and vaccinia viruses.
Pharmacokinetics:
Absorption: Systemic absorption does not occur from ophthalmic application.
Storage
Store between 15-30°C (59-86°F).
Disclaimer: This information is independently developed by MIMS based on Vidarabine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in